- Based on a petition from UCB S.A. (OTCPK:UCBJF), the USPTO's Patent Trial and Appeal Board (PTAB) will review the validity of Roche (OTCQX:RHHBY +0.4%) unit Genentech's U.S. Patent No. 10,011,654 covering antibodies that target interleukin-17A, a proinflammatory cytokine.
- The patent is part of a lawsuit that Genentech filed against Eli Lilly (LLY +0.2%) last year claiming its entitlement to royalties on arthritis med Taltz (ixekizumab), an IL-17A inhibitor. Lilly disagrees and has also filed a petition with the PTAB.